Ameriprise
SYRE icon

Ameriprise’s Spyre Therapeutics SYRE Stock Holding History

Ameriprise’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.6M Buy
356,082
+196,865
+124% +$14.4M 0.01% 1198
2026
Q1 		$8.03M Buy
159,217
+120,961
+316% +$4.56M ﹤0.01% 2092
2025
Q4 		$1.25M Buy
+38,256
New +$1,000K ﹤0.01% 3228

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Ameriprise's SYRE Position: Q2 2026 in Review

Ameriprise increased its Spyre Therapeutics (SYRE) stake by 124% in Q2 2026, buying an estimated $14.4M and bringing the position to 356,082 shares worth $31.6M. The position accounts for 0.01% of the portfolio, ranked #1198.

Ameriprise first reported a position in SYRE in Q4 2025 and has held it in 3 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Ameriprise held 356,082 shares of Spyre Therapeutics worth $31.6M as of Q2 2026.
  • Ameriprise bought 196,865 Spyre Therapeutics shares in Q2 2026, an estimated $14.4M.
  • Spyre Therapeutics made up 0.01% of Ameriprise's portfolio in Q2 2026, its #1198 holding.
  • Ameriprise first reported a position in Spyre Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.